Association of rapamycin and co-stimulation blockade using anti-B7 antibodies in renal allotransplantation in baboon

被引:7
作者
Boulday, G
Ashton-Chess, J
Bernard, P
Karam, G
Vié, H
Moreau, A
Minault, D
Lorré, K
Soulillou, JP
Blancho, G
机构
[1] INSERM, U437, F-44093 Nantes 01, France
[2] CHU Nantes, Hop Hotel Dieu, INSERM, U437 Immonointervent & Allo Xenotransplantat, F-44093 Nantes 01, France
[3] CHU Nantes, Hop Hotel Dieu, INSERM, Inst Transplantat & Rech Transplantat, F-44093 Nantes 01, France
[4] CHU Nantes, Hop Hotel Dieu, Serv Anatomopathol, F-44093 Nantes 01, France
[5] Innogenet, Ghent, Belgium
关键词
anti-B7; antibodies; baboons; co-stimulation; rapamycin; renal allotransplantation;
D O I
10.1093/ndt/gfh126
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Co-stimulation blockade has already been shown to induce transplantation tolerance in rodents, but until now has failed in large animal models. We therefore sought to investigate whether the addition of rapamycin to a co-stimulation blockade regimen could induce tolerance in baboon recipients of a renal allograft and to characterize the immunological characteristics of rejection. Methods. Two baboons were used for a pharmacological and toxicological analysis and received anti-B7.1 and anti-B7 antibodies every other day for 60 days. Three groups of baboons underwent classical heterotopic renal mRNA accumulation in the anti-B7-treated animals, but to a lesser extent in the B7-Rapa group. T cells extracted and cloned from a biopsy taken at a stable post-transplant time showed a lower frequency of anti-donor alloreactivity in vitro than those extracted from a rejected tissue. Nevertheless, these non-responding clones failed to show regulatory activity in vitro. Conclusions. We thus confirm that blocking the CD28/B7 pathway by anti-B7 mAbs could prolong graft survival in baboons, but the addition of rapamycin was insufficient to induce tolerance.allotransplantation; the first group received no treatment (control group; n = 2), the second received a combination of anti-CD80 and anti-CD86 monoclonal antibodies (mAbs) (137 group; n = 4), and the third received the anti-B7 antibody treatment as above with an additional treatment of rapamycin (B7-Rapa; n = 4). Graft survival as well as immunological analyses were performed. Results. Anti-B7 mAb monotherapy prolonged allograft survival in three out of four of the animals, one of whom survived rejection free for 87 days but died from a pulmonary embolism; the fourth animal died without rejection. The addition of rapamycin to the regimen did not prolong survival further; three of the four animals underwent early rejection whereas the fourth survived long term but eventually rejected at day 114. Whereas alloimmunization only occurred in this latter animal, rejection was always characterized by a substantial lymphocyte and monocyte infiltration, associated with a strong pro-inflammatory/cytotoxic mRNA accumulation in the anti-B7-treated animals, but to a lesser extent in the B7-Rapa group. T cells extracted and cloned from a biopsy taken at a stable post-transplant time showed a lower frequency of anti-donor alloreactivity in vitro than those extracted from a rejected tissue. Nevertheless, these non-responding clones failed to show regulatory activity in vitro. Conclusions. We thus confirm that blocking the CD28/137 pathway by anti-B7 mAbs could prolong graft survival in baboons, but the addition of rapamycin was insufficient to induce tolerance.
引用
收藏
页码:1752 / 1760
页数:9
相关论文
共 22 条
[1]   Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys [J].
Bîrsan, T ;
Hausen, B ;
Higgins, JP ;
Hubble, RW ;
Klupp, J ;
Stalder, M ;
Celniker, A ;
Friedrich, S ;
O'Hara, RM ;
Morris, RE .
TRANSPLANTATION, 2003, 75 (12) :2106-2113
[2]   Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning [J].
Durham, MM ;
Bingaman, AW ;
Adams, AB ;
Ha, JW ;
Waitze, SY ;
Pearson, TC ;
Larsen, CP .
JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :1-4
[3]   Highly altered Vβ repertoire of T cells infiltrating long-term rejected kidney allografts [J].
Gagne, K ;
Brouard, S ;
Giral, M ;
Sebille, F ;
Moreau, A ;
Guillet, M ;
Bignon, JD ;
Imbert, BM ;
Cuturi, MC ;
Soulillou, JP .
JOURNAL OF IMMUNOLOGY, 2000, 164 (03) :1553-1563
[4]   CD28/B7 costimulation: A review [J].
Greenfield, EA ;
Nguyen, KA ;
Kuchroo, VK .
CRITICAL REVIEWS IN IMMUNOLOGY, 1998, 18 (05) :389-418
[5]   Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression [J].
Guillot, C ;
Mathieu, P ;
Coathalem, H ;
Le Mauff, B ;
Castro, MG ;
Tesson, L ;
Usal, C ;
Laumonier, T ;
Brouard, S ;
Soulillou, JP ;
Lowenstein, PR ;
Cuturi, MC ;
Anegon, I .
JOURNAL OF IMMUNOLOGY, 2000, 164 (10) :5258-5268
[6]   Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys [J].
Hausen, B ;
Klupp, J ;
Christians, U ;
Higgins, JP ;
Baumgartner, RE ;
Hook, LE ;
Friedrich, S ;
Celnicker, A ;
Morris, RE .
TRANSPLANTATION, 2001, 72 (06) :1128-1137
[7]   Blocking the CD80 and CD86 costimulation molecules: Lessons to be learned from animal models [J].
Jonker, M ;
Ossevoort, MA ;
Vierboom, M .
TRANSPLANTATION, 2002, 73 (01) :S23-S26
[8]   Tolerance to vascularized organ allografts in large-animal models [J].
Kawai, T ;
Sachs, DH ;
Cosimi, AB .
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (05) :516-520
[9]   Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates [J].
Kirk, AD ;
Tadaki, DK ;
Celniker, A ;
Batty, DS ;
Berning, JD ;
Colonna, JO ;
Cruzata, F ;
Elster, EA ;
Gray, GS ;
Kampen, RL ;
Patterson, NB ;
Szklut, P ;
Swanson, J ;
Xu, H ;
Harlan, DM .
TRANSPLANTATION, 2001, 72 (03) :377-384
[10]   Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways [J].
Larsen, CP ;
Elwood, ET ;
Alexander, DZ ;
Ritchie, SC ;
Hendrix, R ;
TuckerBurden, C ;
Cho, HR ;
Aruffo, A ;
Hollenbaugh, D ;
Linsley, PS ;
Winn, KJ ;
Pearson, TC .
NATURE, 1996, 381 (6581) :434-438